Immunotherapy in pancreatic adenocarcinoma - Overcoming barriers to response

Ari Rosenberg, Devalingam Mahalingam

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Pancreatic adenocarcinoma (PAC) remains one of the leading causes of cancer-related death. Despite multiple advances in targeted and immune therapies, the 5-year survival in advanced PAC remains poor. In this review, we discuss some of the unique aspects of the tumor microenvironment (TME) in PAC that may contribute to its resistance to immune therapies, as well as opportunities to potentially overcome some of these inherent barriers. Furthermore, we discuss strategies to enable immune therapies in PAC such as cytotoxic chemotherapy and radiation therapy, cancer vaccines, cytokine based therapy, oncolytic viruses, and adoptive T-cell therapy. Finally, we address a variety of targeted therapies as a strategy to further amplify immune responses in PAC.

Original languageEnglish (US)
Pages (from-to)143-159
Number of pages17
JournalJournal of Gastrointestinal Oncology
Volume9
Issue number1
DOIs
StatePublished - Feb 1 2018
Externally publishedYes

Fingerprint

Immunotherapy
Adenocarcinoma
Oncolytic Virotherapy
Cancer Vaccines
Tumor Microenvironment
Therapeutics
Cell- and Tissue-Based Therapy
Radiotherapy
Cytokines
T-Lymphocytes
Drug Therapy
Neoplasms

Keywords

  • Immunotherapy
  • Pancreatic cancer
  • Targeted therapies
  • Tumor microenvironment (TME)

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Immunotherapy in pancreatic adenocarcinoma - Overcoming barriers to response. / Rosenberg, Ari; Mahalingam, Devalingam.

In: Journal of Gastrointestinal Oncology, Vol. 9, No. 1, 01.02.2018, p. 143-159.

Research output: Contribution to journalReview article

Rosenberg, Ari ; Mahalingam, Devalingam. / Immunotherapy in pancreatic adenocarcinoma - Overcoming barriers to response. In: Journal of Gastrointestinal Oncology. 2018 ; Vol. 9, No. 1. pp. 143-159.
@article{908ab96ede284f7180b3152a74d38889,
title = "Immunotherapy in pancreatic adenocarcinoma - Overcoming barriers to response",
abstract = "Pancreatic adenocarcinoma (PAC) remains one of the leading causes of cancer-related death. Despite multiple advances in targeted and immune therapies, the 5-year survival in advanced PAC remains poor. In this review, we discuss some of the unique aspects of the tumor microenvironment (TME) in PAC that may contribute to its resistance to immune therapies, as well as opportunities to potentially overcome some of these inherent barriers. Furthermore, we discuss strategies to enable immune therapies in PAC such as cytotoxic chemotherapy and radiation therapy, cancer vaccines, cytokine based therapy, oncolytic viruses, and adoptive T-cell therapy. Finally, we address a variety of targeted therapies as a strategy to further amplify immune responses in PAC.",
keywords = "Immunotherapy, Pancreatic cancer, Targeted therapies, Tumor microenvironment (TME)",
author = "Ari Rosenberg and Devalingam Mahalingam",
year = "2018",
month = "2",
day = "1",
doi = "10.21037/jgo.2018.01.13",
language = "English (US)",
volume = "9",
pages = "143--159",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "1",

}

TY - JOUR

T1 - Immunotherapy in pancreatic adenocarcinoma - Overcoming barriers to response

AU - Rosenberg, Ari

AU - Mahalingam, Devalingam

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Pancreatic adenocarcinoma (PAC) remains one of the leading causes of cancer-related death. Despite multiple advances in targeted and immune therapies, the 5-year survival in advanced PAC remains poor. In this review, we discuss some of the unique aspects of the tumor microenvironment (TME) in PAC that may contribute to its resistance to immune therapies, as well as opportunities to potentially overcome some of these inherent barriers. Furthermore, we discuss strategies to enable immune therapies in PAC such as cytotoxic chemotherapy and radiation therapy, cancer vaccines, cytokine based therapy, oncolytic viruses, and adoptive T-cell therapy. Finally, we address a variety of targeted therapies as a strategy to further amplify immune responses in PAC.

AB - Pancreatic adenocarcinoma (PAC) remains one of the leading causes of cancer-related death. Despite multiple advances in targeted and immune therapies, the 5-year survival in advanced PAC remains poor. In this review, we discuss some of the unique aspects of the tumor microenvironment (TME) in PAC that may contribute to its resistance to immune therapies, as well as opportunities to potentially overcome some of these inherent barriers. Furthermore, we discuss strategies to enable immune therapies in PAC such as cytotoxic chemotherapy and radiation therapy, cancer vaccines, cytokine based therapy, oncolytic viruses, and adoptive T-cell therapy. Finally, we address a variety of targeted therapies as a strategy to further amplify immune responses in PAC.

KW - Immunotherapy

KW - Pancreatic cancer

KW - Targeted therapies

KW - Tumor microenvironment (TME)

UR - http://www.scopus.com/inward/record.url?scp=85041713175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041713175&partnerID=8YFLogxK

U2 - 10.21037/jgo.2018.01.13

DO - 10.21037/jgo.2018.01.13

M3 - Review article

AN - SCOPUS:85041713175

VL - 9

SP - 143

EP - 159

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 1

ER -